Inhibikase Therapeutics reported net income of -$19.59M for the quarter ended Jun 2026. This income statement covers 26 quarters of results from Mar 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | ||||||||||||||||||||||||||
| Revenue | 0.33M | 0.00M | 0.05M | 0.01M | 0.01M | 0.06M | 0.06M | 0.12M | 0.08M | 1.00 | ||||||||||||||||
| Operating items | ||||||||||||||||||||||||||
| Research & DevelopmentR&D | 3.15M | 3.39M | 3.02M | 2.98M | 2.98M | 3.05M | 2.85M | 4.54M | 3.23M | 3.00M | 2.75M | 3.08M | 4.19M | 7.19M | 10.51M | 5.27M | 7.65M | 6.36M | 10.84M | 13.39M | ||||||
| Selling, General & AdministrativeSG&A | 1.64M | 1.65M | 1.67M | 1.66M | 1.54M | 1.34M | 1.93M | 1.78M | 1.62M | 1.40M | 2.03M | 1.97M | 1.64M | 5.74M | 5.25M | 5.92M | 5.61M | 6.77M | 7.38M | 7.66M | ||||||
| Other Operating ExpensesOther Opex | -1.16M | -0.36M | -0.49M | 0.64M | -0.37M | |||||||||||||||||||||
| Operating ExpensesOpex | 4.80M | 5.04M | 4.69M | 4.65M | 4.52M | 4.40M | 4.78M | 6.32M | 4.85M | 4.40M | 4.78M | 5.05M | 5.83M | 12.93M | 14.60M | 10.83M | 12.77M | 13.78M | 17.84M | 21.05M | ||||||
| Operating IncomeOp. Inc | -4.47M | -5.04M | -4.64M | -4.64M | -4.51M | -4.33M | -4.71M | -6.20M | -4.77M | -4.40M | -4.78M | -5.05M | -5.83M | -12.93M | -14.60M | -10.83M | -12.77M | -13.78M | -17.84M | -21.05M | ||||||
| EBIT | -4.47M | -5.04M | -4.64M | -4.64M | -4.51M | -4.33M | -4.71M | -6.20M | -4.77M | -4.40M | -4.78M | -5.05M | -5.83M | -12.93M | -14.60M | -10.83M | -12.77M | -13.78M | -17.84M | -21.05M | ||||||
| Non-operating items | ||||||||||||||||||||||||||
| Non Operating Interest Expenses | 157.00 | 158.00 | 5.00 | |||||||||||||||||||||||
| Non Operating Investment IncomeNon-Op. Investment Inc. | 0.03M | -0.17M | 0.00M | -0.00M | 776.00 | 0.00M | -0.04M | 0.04M | -0.00M | -0.00M | 0.03M | -0.05M | -0.05M | |||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.02M | |||||||||||||||||||||||||
| Net income details | ||||||||||||||||||||||||||
| EBT | -4.47M | -5.04M | -4.64M | -4.64M | -4.49M | -4.33M | -4.71M | -6.20M | -4.77M | -4.40M | -4.78M | -5.05M | -5.83M | -12.93M | -14.60M | -10.83M | -12.77M | -13.78M | -17.84M | -21.05M | ||||||
| Profit After TaxPAT | -4.47M | -5.04M | -4.64M | -4.64M | -4.49M | -4.28M | -4.48M | -5.78M | -4.60M | -4.18M | -4.65M | -4.96M | -5.78M | -12.13M | -13.68M | -9.92M | -11.93M | -12.73M | -16.38M | -19.59M | ||||||
| Income from Continuing OperationsIncome (Continuing) | -4.47M | -5.04M | -4.64M | -4.64M | -4.49M | -4.33M | -4.71M | -6.20M | -4.77M | -4.40M | -4.78M | -5.05M | -5.83M | -12.93M | -14.60M | -10.83M | -12.77M | -13.78M | -17.84M | -21.05M | ||||||
| Consolidated Net IncomeConsol Net Inc. | -4.47M | -5.04M | -4.64M | -4.64M | -4.49M | -4.33M | -4.71M | -6.20M | -4.77M | -4.40M | -4.78M | -5.05M | -5.83M | -12.93M | -14.60M | -10.83M | -12.77M | -13.78M | -17.84M | -21.05M | ||||||
| Income towards Parent CompanyParent Net Inc | -4.47M | -5.04M | -4.64M | -4.64M | -4.49M | -4.33M | -4.71M | -6.20M | -4.77M | -4.40M | -4.78M | -5.05M | -5.83M | -12.93M | -14.60M | -10.83M | -12.77M | -13.78M | -17.84M | -21.05M | ||||||
| Net Income towards Common StockholdersNet Income | -4.47M | -5.04M | -4.64M | -4.64M | -4.49M | -4.33M | -4.71M | -6.20M | -4.77M | -4.40M | -4.78M | -5.05M | -5.83M | -12.93M | -14.60M | -10.83M | -12.77M | -13.78M | -17.84M | -21.05M | ||||||
| Additional items | ||||||||||||||||||||||||||
| EPS (Basic) | -1.07 | -1.66 | -1.10 | -1.10 | -1.07 | -1.03 | -1.03 | -1.19 | -0.89 | -0.83 | -0.75 | -0.67 | -0.66 | -0.55 | -0.16 | -0.12 | -0.14 | -0.14 | -0.10 | -0.12 | ||||||
| EPS (Diluted) | -1.07 | -1.66 | -1.10 | -1.10 | -1.07 | -1.03 | -1.03 | -1.19 | -0.89 | -0.83 | -0.75 | -0.67 | -0.66 | -0.55 | -0.16 | -0.12 | -0.14 | -0.14 | -0.10 | -0.12 | ||||||
| Shares Outstanding | 4.19M | 3.03M | 4.20M | 4.20M | 4.20M | 4.20M | 4.59M | 5.23M | 5.34M | 5.33M | 6.34M | 7.54M | 8.88M | 23.71M | 89.54M | 90.01M | 90.05M | 98.31M | 172.31M | 174.57M | ||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 4.19M | 3.03M | 4.20M | 4.20M | 4.20M | 4.20M | 4.59M | 5.23M | 5.34M | 5.33M | 6.34M | 7.54M | 8.88M | 23.71M | 89.54M | 90.01M | 90.05M | 98.31M | 172.31M | 174.57M | ||||||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 4.19M | 3.03M | 4.20M | 4.20M | 4.20M | 4.20M | 5.18M | 5.29M | 5.36M | 6.19M | 6.48M | 7.22M | 7.46M | 23.71M | 74.34M | 74.52M | 74.81M | 98.31M | 172.31M | 174.57M | ||||||
| EBITDA | -4.47M | -5.04M | -4.64M | -4.64M | -4.51M | -4.33M | -4.71M | -6.20M | -4.77M | -4.40M | -4.78M | -5.05M | -5.83M | -12.93M | -14.60M | -10.83M | -12.77M | -13.78M | -17.84M | -21.05M | ||||||
| Interest ExpensesInt Expense | 157.00 | 158.00 | 5.00 |